HUTCHMED (HCM) News Today $14.20 +0.88 (+6.61%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period HUTCHMED (NASDAQ:HCM) Shares Gap Up - What's Next?HUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?January 17 at 12:46 PM | marketbeat.comHUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume - Here's What HappenedHUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume - Here's WhyJanuary 16, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Should You Sell?HUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's WhyJanuary 15, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Stock Price Passes Below 50 Day Moving Average - What's Next?HUTCHMED (NASDAQ:HCM) Share Price Crosses Below 50 Day Moving Average - Here's What HappenedJanuary 15, 2025 | marketbeat.comHutchmed announces NMPA approval for Orpathys supplemental new drug applicationJanuary 14, 2025 | markets.businessinsider.comHUTCHMED’s ORPATHYS® Receives Full NMPA Approval for Expanded NSCLC TreatmentJanuary 13, 2025 | tipranks.comHUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCJanuary 13, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Trading Down 4.5% - Should You Sell?HUTCHMED (NASDAQ:HCM) Stock Price Down 4.5% - Here's WhyJanuary 7, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume - Still a Buy?HUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume - Still a Buy?January 6, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Here's What HappenedHUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?January 2, 2025 | marketbeat.comChinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 MillionJanuary 2, 2025 | benzinga.comHUTCHMED's Combination Therapy For Lung Cancer Granted Priority Review By NMPAJanuary 1, 2025 | markets.businessinsider.comHUTCHMED’s Lung Cancer Drug Combo Gains Priority ReviewJanuary 1, 2025 | tipranks.comHUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor TherapyJanuary 1, 2025 | globenewswire.comBillionaire Li Ka-shing's Hutchmed in $608 mln health unit stake salesJanuary 1, 2025 | reuters.comHUTCHMED (China) Limited (NASDAQ:HCM) Sees Significant Decline in Short InterestHUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totalling 467,900 shares, a drop of 8.1% from the November 30th total of 509,300 shares. Based on an average daily volume of 95,100 shares, the days-to-cover ratio is presently 4.9 days.January 1, 2025 | marketbeat.comHUTCHMED Sells Major Stake to Focus on Core BusinessJanuary 1, 2025 | tipranks.comHUTCHMED Announces US$608 million Divestment of Non-Core Joint VentureJanuary 1, 2025 | globenewswire.comHUTCHMED Expands Brokerage Partnerships in LondonDecember 31, 2024 | tipranks.comHUTCHMED’s Share Option Scheme Update and Stock IssuanceDecember 30, 2024 | tipranks.comJane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM)Jane Street Group LLC lifted its stake in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 362.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 62,997 shares of the company's stock afterDecember 29, 2024 | marketbeat.comPaycor HCM: Positive On The Mid-Term Growth Outlook (Rating Upgrade)December 25, 2024 | seekingalpha.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's WhyHUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's What HappenedDecember 16, 2024 | marketbeat.comHutchmed announces BTD in China for Orpathys, Tagrisso combinationDecember 12, 2024 | markets.businessinsider.comHUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)December 12, 2024 | finance.yahoo.comHUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)December 12, 2024 | globenewswire.comHUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor TherapyDecember 11, 2024 | globenewswire.comBNP Paribas Financial Markets Sells 132,711 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)BNP Paribas Financial Markets trimmed its position in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 69.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 58,443 shares of the company's stock after sellDecember 10, 2024 | marketbeat.comInnovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial CancerDecember 3, 2024 | prnewswire.comHUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial CancerDecember 3, 2024 | globenewswire.comHUTCHMED (China) Limited (NASDAQ:HCM) Stake Cut by Bellevue Group AGBellevue Group AG decreased its holdings in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 97.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,015 shares of the company's stock afterDecember 2, 2024 | marketbeat.comHUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current TermsNovember 28, 2024 | markets.businessinsider.comHUTCHMED Announces Renewal Of ORPATHYS Inclusion In China's NRDLNovember 28, 2024 | markets.businessinsider.comHUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current TermsNovember 28, 2024 | globenewswire.comHutchmed to receive milestone payment following Takeda launch of FruzaqlaNovember 22, 2024 | msn.comHUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in JapanNovember 21, 2024 | globenewswire.comHUTCHMED (China) (NASDAQ:HCM) Stock, Option ChainNovember 21, 2024 | benzinga.comHUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board CommitteeNovember 20, 2024 | globenewswire.comHUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by M&G PlcM&G Plc raised its holdings in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 98.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 267,231 shares of the company's stock after acquiring an additional 132,333 shares during the quarterNovember 9, 2024 | marketbeat.comHUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia CongressNovember 5, 2024 | globenewswire.comHUTCHMED (NASDAQ:HCM) Stock Rating Upgraded by StockNews.comStockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a research report on Monday.November 4, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Should You Buy?HUTCHMED (NASDAQ:HCM) Shares Gap Up - Here's WhyNovember 1, 2024 | marketbeat.comHUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by TakedaOctober 31, 2024 | finance.yahoo.comHUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by TakedaOctober 31, 2024 | globenewswire.comHUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume - Here's WhyHUTCHMED (NASDAQ:HCM) Sees Large Volume Increase - What's Next?October 18, 2024 | marketbeat.comHUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trialOctober 16, 2024 | globenewswire.comHUTCHMED (NASDAQ:HCM) Stock Price Down 2.3% - Should You Sell?HUTCHMED (NASDAQ:HCM) Shares Down 2.3% - Here's WhyOctober 11, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down to $20.82HUTCHMED (NASDAQ:HCM) Shares Gap Down to $20.82October 3, 2024 | marketbeat.comRenaissance Technologies LLC Grows Position in HUTCHMED (China) Limited (NASDAQ:HCM)Renaissance Technologies LLC raised its holdings in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 74.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 131,300 shares of the company'October 3, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeHUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading VolumeOctober 2, 2024 | marketbeat.com Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address HCM Media Mentions By Week HCM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HCM News Sentiment▼0.800.44▲Average Medical News Sentiment HCM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HCM Articles This Week▼52▲HCM Articles Average Week Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ROIV News ASND News BPMC News RVMD News BBIO News LNTH News LEGN News ELAN News CYTK News NUVL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HCM) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HCM Stock Alerts